News Releases

Date Title
01/23/2017 Summary ToggleEnanta Pharmaceuticals to Host Conference Call on February 8 at 4:30 p.m. ET to Discuss Financial Results for its Fiscal First Quarter Ended December 31, 2016
01/09/2017 Summary ToggleEnanta Announces High SVR12 Rates Achieved in Genotype 1 Chronic HCV Infected Japanese Patients with Eight Weeks of Treatment with AbbVie’s Investigational, Pan-Genotypic, Ribavirin-free Regimen of Glecaprevir/Pibrentasvir (G/P)
01/06/2017 Summary ToggleEnanta Pharmaceuticals Announces Highlights of Business Overview and Update on its Research and Development Programs to be Presented at the 35th Annual J.P. Morgan Healthcare Conference
01/04/2017 Summary ToggleFDA Grants Fast Track Designation to Enanta’s FXR Agonist Candidate, EDP-305, for the treatment of NASH with Liver Fibrosis
12/22/2016 Summary ToggleEnanta Pharmaceuticals to Present at the 35th Annual J.P. Morgan Healthcare Conference
12/19/2016 Summary ToggleEnanta Pharmaceuticals Announces AbbVie’s Submission of NDA for Investigational, Pan-Genotypic HCV Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of Genotypes 1 through 6 of Chronic Hepatitis C Virus (HCV)
11/22/2016 Summary ToggleEnanta Pharmaceuticals Announces the Appointment of Dr. Lesley Russell to Its Board of Directors
11/21/2016 Summary ToggleEnanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2016
11/15/2016 Summary ToggleEnanta Pharmaceuticals Announces AbbVie’s Investigational, Pan-Genotypic Regimen of Glecaprevir/Pibrentasvir (G/P) Shows High SVR Rates in Chronic Hepatitis C Patients with Severe Chronic Kidney Disease
11/11/2016 Summary ToggleEnanta Announces Eight Weeks of Treatment with AbbVie’s Investigational, Pan-Genotypic Regimen of Glecaprevir/Pibrentasvir (G/P) Achieved High SVR Rates Across All Major Genotypes of Chronic Hepatitis C